INDP Indaptus Therapeutics Inc

$INDP — INDP continues to be one of the wildest smaller healthcare names after gaining roughly 249% during September. The company raised around $24M and is exploring early research around a sleep-related device following the Decoy20 reset. That makes this less about the old pipeline and more about what management decides to do with its newly raised capital. Definitely a speculative one, but the strategic pivot has kept retail attention elevated

$INDP — INDP has basically become a corporate-reset story. After discontinuing Decoy20 enrollment, the company raised roughly $24M and began exploring a new sleep/neurotechnology direction. With fresh capital and a completely different potential strategy, the important question now is what management actually decides to build or acquire. 👀

$INDP — September has been wild for Indaptus. The company raised roughly $24M and is exploring a new direction involving neurotechnology for sleep-related conditions after stopping enrollment in its Decoy20 cancer program. Definitely a major strategy shift, and now the question is how management puts that new capital to work.

$INDP closed a $24M private placement stock purchase agreement, extending its funding deadline to Oct 16.

$INDP The closing date of the private placement from earlier in Sept has been extended to Oct 16. https://www.sec.gov/ix?doc=/Archives/edgar/data/1857044/000149315226045040/form8-k.htm Details of the private placement 👇

$INDP i give up, have no idea why it's doing this, but just as likely to go down same amount tomorrow